Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson's disease.
Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson's disease.
复制标题
DOI：
10.1038/srep13888
复制
发表时间：
2015-09-14
影响因子：
4.6
通讯作者：
Cai Z
中科院分区：
文献类型：
--
作者：
Luan H;Liu LF;Tang Z;Zhang M;Chua KK;Song JX;Mok VC;Li M;Cai Z
尿液代谢表型与帕金森病(PD)的发生有关。然而，使用综合代谢组学方法的研究很少调查尿标记物变化与帕金森病临床症状进展之间的相关性。采用气相色谱-质谱仪(GC-MS)和液质联用仪(LC-MS)对特发性帕金森病患者(早、中、晚期)和正常对照组的尿液代谢表型进行了全面的质量控制研究，旨在寻找诊断特发性帕金森病的潜在尿代谢物标志物。特发性帕金森病患者的GC-MS和LC-MS代谢谱均明显不同于正常对照组。18种差异表达的代谢物被鉴定为构成与特发性帕金森病进展相关的独特代谢标志物。在支链氨基酸代谢、甘氨酸衍生、类固醇激素生物合成、色氨酸代谢和苯丙氨酸代谢中观察到相关代谢途径的变化。全面、连续的代谢图谱显示与特发性帕金森病进展相关的尿标记物的变化。这种分析依赖于非侵入性采样，是对现有临床模式的补充。
Urine metabolic phenotyping has been associated with the development of Parkinson’s disease (PD). However, few studies using a comprehensive metabolomics approach have investigated the correlation between changes in the urinary markers and the progression of clinical symptoms in PD. A comprehensive metabolomic study with robust quality control procedures was performed using gas chromatography - mass spectrometry (GC - MS) and liquid chromatography - mass spectrometry (LC - MS) to characterize the urinary metabolic phenotypes of idiopathic PD patients at three stages (early, middle and advanced) and normal control subjects, with the aim of discovering potential urinary metabolite markers for the diagnosis of idiopathic PD. Both GC-MS and LC-MS metabolic profiles of idiopathic PD patients differed significantly from those of normal control subjects. 18 differentially expressed metabolites were identified as constituting a unique metabolic marker associated with the progression of idiopathic PD. Related metabolic pathway variations were observed in branched chain amino acid metabolism, glycine derivation, steroid hormone biosynthesis, tryptophan metabolism, and phenylalanine metabolism. Comprehensive, successive metabolomic profiling revealed changes in the urinary markers associated with progression of idiopathic PD. This profiling relies on noninvasive sampling, and is complementary to existing clinical modalities.